Pfizer Looks Vindicated as Covid Product Sales Defy Skeptical Analyst Forecasts
- Pfizer said Wall Street underestimated 2023 Covid market
- Earlier this year, Pfizer forecast $21.5B in 2023 Covid product sales
- Analysts were skeptical of Pfizer's lofty Covid sales forecast
- Pfizer looking prescient as Covid product sales remain strong
- Article requires Barron's subscription to read full details
